Table 1.
Patient and Clinical Characteristics by TTC Among Patients With Stage I to III BC Diagnosed Between 1997 and 2011 and Treated With Adjuvant Chemotherapy
| Characteristic | All Patients (N = 6,827) |
TTC (days) |
P* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤ 30 (n = 2,716) |
31-60 (n = 2,994) |
≥ 61 (n = 1,117) |
|||||||
| No. | % | No. | % | No. | % | No. | % | ||
| Age at diagnosis, years | |||||||||
| Median | 50 | 49 | 50 | 50 | |||||
| Range | 19-85 | 21-83 | 19-85 | 23-82 | |||||
| Race/ethnicity | .28 | ||||||||
| White | 4,927 | 72.2 | 1,938 | 71.4 | 2,161 | 72.2 | 828 | 74.1 | |
| African American | 646 | 9.5 | 254 | 9.4 | 303 | 10.1 | 89 | 8.0 | |
| Hispanic | 912 | 13.4 | 376 | 13.8 | 388 | 13.0 | 148 | 13.2 | |
| Other | 342 | 5 | 148 | 5.4 | 142 | 4.7 | 52 | 4.7 | |
| Pathologic tumor size | .56 | ||||||||
| T1 | 3,595 | 53.8 | 1,415 | 53.2 | 1,598 | 54.6 | 582 | 53.0 | |
| T2 | 2,642 | 39.5 | 1,062 | 39.9 | 1,131 | 38.6 | 449 | 40.9 | |
| T3 | 420 | 6.3 | 173 | 6.5 | 183 | 6.3 | 64 | 5.8 | |
| T4 | 28 | 0.4 | 9 | 0.3 | 15 | 0.5 | 4 | 0.4 | |
| Nodal status | .75 | ||||||||
| N0 | 2,804 | 41.7 | 1,101 | 41.1 | 1,258 | 42.7 | 445 | 40.5 | |
| N1 | 2,539 | 37.8 | 1,009 | 37.7 | 1,102 | 37.4 | 428 | 39.0 | |
| N2 | 872 | 13 | 355 | 13.3 | 371 | 12.6 | 146 | 13.3 | |
| N3 | 506 | 7.5 | 213 | 8.0 | 214 | 7.3 | 79 | 7.2 | |
| Subtype | .008 | ||||||||
| Hormone receptor–positive | 3,834 | 65.4 | 1,604 | 67.7 | 1,646 | 64.5 | 584 | 61.9 | |
| HER2-positive | 1,142 | 19.5 | 445 | 18.8 | 493 | 19.3 | 204 | 21.6 | |
| Triple-negative | 889 | 15.2 | 321 | 13.5 | 412 | 16.2 | 156 | 16.5 | |
| Nuclear grade | .18 | ||||||||
| I | 279 | 4.3 | 101 | 3.9 | 133 | 4.6 | 45 | 4.3 | |
| II | 2,552 | 39.2 | 1,052 | 40.8 | 1,083 | 37.8 | 417 | 39.5 | |
| III | 3,671 | 56.5 | 1,424 | 55.3 | 1,652 | 57.6 | 595 | 56.3 | |
| Lymphovascular invasion | .09 | ||||||||
| Negative | 4,600 | 67.4 | 1,795 | 66.1 | 2,027 | 67.7 | 778 | 69.7 | |
| Positive | 2,227 | 32.6 | 921 | 33.9 | 967 | 32.3 | 339 | 30.3 | |
| Surgery | .83 | ||||||||
| BCS | 3,042 | 44.6 | 1,214 | 44.7 | 1,323 | 44.2 | 505 | 45.2 | |
| Mastectomy | 3,784 | 55.4 | 1,502 | 55.3 | 1,670 | 55.8 | 612 | 54.8 | |
| No. of comorbidities† | .46 | ||||||||
| 0 | 2,142 | 31.4 | 853 | 31.4 | 924 | 30.9 | 365 | 32.7 | |
| 1-2 | 2,970 | 43.5 | 1,162 | 42.8 | 1,311 | 43.8 | 497 | 44.5 | |
| 3-4 | 1,387 | 20.3 | 558 | 20.5 | 619 | 20.7 | 210 | 18.8 | |
| 5-12 | 328 | 4.8 | 143 | 5.3 | 140 | 4.7 | 45 | 4.0 | |
| Trastuzumab among HER2-positive patients (n = 1,142) | .95 | ||||||||
| No | 551 | 48.2 | 212 | 47.6 | 240 | 48.7 | 99 | 48.5 | |
| Yes | 591 | 51.8 | 233 | 52.4 | 253 | 51.3 | 105 | 51.5 | |
| Adjuvant chemotherapy among triple-negative patients (n = 889) | .98 | ||||||||
| Anthracycline-based | 237 | 26.7 | 84 | 26.2 | 109 | 26.5 | 44 | 28.2 | |
| Anthracycline-based + taxane-based | 531 | 59.7 | 195 | 60.7 | 246 | 59.7 | 90 | 57.7 | |
| Other | 121 | 13.6 | 42 | 13.1 | 57 | 13.8 | 22 | 14.1 | |
Abbreviations: BC, breast cancer; BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2; TTC, time to initiation of adjuvant chemotherapy.
*
P value from F test.
†
Comorbidities evaluated included cardiac disease, vascular disease, diabetes mellitus, dyslipidemia, osteopenia/osteoporosis, connective tissue disorder, infectious diseases, and other.